Showing 9161-9170 of 19239 results for "".
- Vitamin D Linked to Shifts in Non-Coding RNA Networks During Zika Virus Infection in Human Macrophageshttps://reachmd.com/news/vitamin-d-linked-to-shifts-in-non-coding-rna-networks-during-zika-virus-infection-in-human-macrophages/2485571/A new exploratory transcriptomic study suggests that vitamin D conditioning is associated with broad shifts in non-coding RNA expression and predicted regulatory networks in human macrophages infected with Zika virus, highlighting candidate lnc
- Microbiome-Targeted Approaches in Post-Infectious IBS: A Pilot Study Reviewhttps://reachmd.com/news/microbiome-targeted-approaches-in-post-infectious-ibs-a-pilot-study-review/2485545/Targeted microbiome modulation produced clinically meaningful benefit in a pilot case–control study for post-infectious irritable bowel syndrome (PI-IBS), showin
- Rising Rates of Psychosis in Younger Generations: A Clinical and Service Implication Reviewhttps://reachmd.com/news/rising-rates-of-psychosis-in-younger-generations-a-clinical-and-service-implication-review/2485547/A recent study in Ontario shows a sharp rise in new psychosis diagnoses among younger birth cohorts — a finding with immediate implications for early intervention and service-capacity planning. Ne
- New Compounds Identified for ROS1 G2032R Mutationhttps://reachmd.com/news/new-compounds-identified-for-ros1-g2032r-mutation/2485501/A recent computational study has identified four small molecules that may inhibit the crizotinib-resistant ROS1 G2032R mutation found in non-small-cell lung cancer (NSCLC). Resistance to ROS1-targeted therapies,
- Icotrokinra Maintains Psoriasis Responses With Continuous Treatmenthttps://reachmd.com/news/icotrokinra-maintains-psoriasis-responses-with-continuous-treatment/2485554/Continuous treatment with icotrokinra resulted in durable psoriasis control through one year, while treatment withdrawal was associated with rapid loss of response, according to “Maintenance of Response With Icotrokinra for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results From the Ph
- Povorcitinib Improves Lesion Burden and Pain in Hidradenitis Suppurativahttps://reachmd.com/news/povorcitinib-improves-lesion-burden-and-pain-in-hidradenitis-suppurativa/2485551/Oral povorcitinib produced early and sustained improvements in lesion burden and pain in patients with moderate-to-severe hidradenitis suppurativa (HS), according to “Effect of Povorcitinib on Hidradenitis Suppurativa Lesions Through 24 Weeks in STOP-HS Trials,” a poster by Jennifer L. Hsiao, MD,
- ORKA-001 Phase 1 Data Support Potential Once-Yearly IL-23 Dosinghttps://reachmd.com/news/orka-001-phase-1-data-support-potential-once-yearly-il-23-dosing/2485550/A half-life–extended IL-23p19 monoclonal antibody demonstrated sustained pharmacokinetics and favorable tolerability that may support once-yearly dosing in plaque psoriasis, according to “Phase 1 Clinical Data of ORKA-001, a Novel Half-Life–Extended IL-23p19 Monoclonal Antibody,” a poster by Jame
- Dupilumab Produces Early and Sustained Improvements in CSU Activityhttps://reachmd.com/news/dupilumab-produces-early-and-sustained-improvements-in-csu-activity/2485548/Dupilumab produced early and sustained reductions in urticaria activity in patients with chronic spontaneous urticaria (CSU), according to “Dupilumab Provides Early and Sustained Improvement in Urticaria Activity in Patients With Chronic Spontaneous Urticaria,” a poster by Jonathan A. Bernstein,
- Molecular Evolution of SARS-CoV-2 in Immunocompromised Patients: Clinical Insights and Management Strategieshttps://reachmd.com/news/molecular-evolution-of-sars-cov-2-in-immunocompromised-patients-clinical-insights-and-management-strategies/2485522/Replication‑competent SARS‑CoV‑2 persisted for months to years in three immunocompromised patients, driving intra‑host viral evolution and prompting reconsideration of surveillance and treatment strategies. The team performed detailed longitudinal virologic assessmen
- Telesurgery vs. Robotic Surgery: Innovations in Urologic Oncologyhttps://reachmd.com/news/telesurgery-vs-robotic-surgery-innovations-in-urologic-oncology/2485531/A randomized, multicenter non-inferiority trial found remote telesurgery to be non-inferior to local robotic surgery for radical prostatectomy and partial nephrec